logo
How to trick your nervous system into calming down when you're stressed at work

How to trick your nervous system into calming down when you're stressed at work

Fast Company03-07-2025
Understanding how your body works can be the key to reducing stress. For example, you're probably aware of your fight-or-flight response —the body's way of preparing itself when it believes it's being threatened. What happens is your sympathetic nervous system is activated, pumping adrenaline and glucocorticoid steroids into your system that give you hyper focus, energy and strength to handle the situation.
Fight-or-flight was a survival mechanism during hunter-gatherer times, when the threat of wild animals was real. Today, however, it's often triggered by non-life-or-death events, such as the evening news, tight deadlines, or traffic.
On the flipside of fight-or-flight is rest-and-digest. It's the body's way of rebalancing itself after the danger has passed. In this case, your parasympathetic nervous system is in charge, decreasing your heart rate and blood pressure and providing a sense of calm.
Sometimes, though, the body has a hard time getting back into rest-and-digest. It stays in a state of stress and anxiety. When this happens, it's often due to your vagal tone, which is the activity in your vagus nerve, says Kevin Tracey, M.D., author of The Great Nerve: The New Science of the Vagus Nerve and How to Harness Its Healing..
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

In Vitro Diagnostics Market Size to Exceed USD 132.18 Bn by 2034
In Vitro Diagnostics Market Size to Exceed USD 132.18 Bn by 2034

Yahoo

time26 minutes ago

  • Yahoo

In Vitro Diagnostics Market Size to Exceed USD 132.18 Bn by 2034

According to Precedence Research, the global in vitro diagnostics (IVD) market size is expected to exceed USD 132.07 billion by 2034, increasing from USD 104.01 billion in 2025, with a CAGR of 2.30% between 2025 and 2034. Growth is fueled by rising chronic disease prevalence, demand for early detection, and rapid adoption of advanced molecular testing technologies. Ottawa, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The worldwide in vitro diagnostics market size accounted for USD 102.05 billion in 2024, and is predicted to grow from USD 104.01 billion in 2025 to approximately USD 132.07 billion by 2034. The growing awareness about the early detection of diseases and the growing prevalence of chronic diseases drive market growth. Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for Before You Buy – Get the Sample Report@ In Vitro Diagnostics Industry – Strategic Insights In terms of revenue, the in vitro diagnostics market has been calculated at USD 104.01 billion in 2025. It is anticipated to reach over USD 132.07 billion by 2034. North America captured a 42% revenue share of the global market in 2024. Asia Pacific is expected to grow at a significant CAGR between 2025 and 2034. By product, the reagents segment held the major market share of 66.07% in 2024. By product, the instruments segment is expanding at a solid CAGR from 2025 to 2034. By test location, the point-of-care segment held a significant share in 2024. By test location, the home care segment is anticipated to witness considerable growth from 2025 to 2034 By technology, the molecular diagnostics segment contributed the largest market share of 33.06% in 2024. By technology, the immunoassay segment is projected to grow at a considerable CAGR from 2025 to 2034. By application, the infectious disease segment accounted for the biggest market share of 52.53% in 2024. By application, the oncology segment is growing at a notable CAGR between 2025 and 2034. By end user, the hospital segment held the largest market share of 37.89% in 2024. In Vitro Diagnostics Market Revenue (USD Million) By Product Type 2022-2024 Product 2022 2023 2024 Instruments 28,950.5 26,909.55 25,379.75 Reagents 75,883.9 70,996.28 67,404.76 Services 10,654.3 9,861.36 9,264.58 In Vitro Diagnostics Market Revenue (USD Million) By Technology 2022-2024 Technology 2022 2023 2024 Immunoassay 34,688.2 32,433.72 30,774.22 Hematology 6,827.4 6,345.41 5,984.69 Clinical Chemistry 20,236.7 18,978.14 18,061.02 Molecular Diagnosis 38,255.7 35,662.26 33,736.25 Coagulation 4,680.5 4,328.27 4,061.72 Microbiology 6,384.9 5,916.29 5,563.15 Others 4,415.3 4,103.12 3,868.03 In Vitro Diagnostics Market Revenue (USD Million) By Application 2022-2024 Application 2022 2023 2024 Infectious Diseases 61,149.9 56,833.27 53,602.44 Diabetes 9,146.6 8,475.36 7,969.48 Oncology 8,727.7 8,323.38 8,055.14 Cardiology 9,104.3 8,538.03 8,125.43 Nephrology 6,633.3 6,127.88 5,744.71 Autoimmune Diseases 5,350.6 4,987.83 4,718.45 Drug Testing 3,986.6 3,757.30 3,593.52 Others 11,389.6 10,724.14 10,239.92 Available for Instant Download – Order This Premium Market Study Today@ In Vitro Diagnostics Market Overview In vitro diagnostics (IVD) are tests conducted on samples retrieved from human bodily tissues and fluids. IVD performs on biological samples like tissue, blood, urine, and others, and tests are performed in the laboratory. Tests help to diagnose various infections, diseases, & other health issues, and monitor patient health. IVD helps in the early detection of diseases, avoids the spreading of diseases, and enhances patient care. The common IVD tests are COVID-19, HIV tests, pregnancy tests, blood glucose monitoring, and many more. Factors like a rise in personalised medicines, increasing awareness about the early detection of diseases, growing cardiovascular diseases, and technological advancements in IVD contribute to the in vitro diagnostics market. Top Types of IVD Technologies in 2025: Technology Working Principle Uses ELISA Capturing the antigen-antibody reaction Autoimmune disorder HIV Lyme Disease NGS DNA fragmentation and parallel sequencing Cancer Genetic disorders Infectious diseases CLIA The binding antibody and the corresponding antigenChemiluminescence reactions Hormone imbalances Tumor detection Diabetes Hypertension PCR/RT-PCR Amplification of DNA & RNA Genetic disorder Infectious diseases Flow Cytometry Laser-based techniques for the analysis of cells Blood disorders Immune system problems Myelodysplastic syndromes Lateral Flow Sample amplification and target binding Pregnancy Respiratory infections Mosquito-borne diseases Sexually transmitted infections ➤ In Vitro Diagnostics Market Major Trends: Advanced Lateral Flow Tests (LFTs) Beyond COVID-19Evolved LFTs are now capable of detecting a wide array of substances—from vitamin D and iron to stroke markers—using novel samples like fingerprint sweat or pet vomit. Their versatility is rapidly expanding across healthcare, environmental, and even animal diagnostics. Integrated Point-of-Care and At-Home Nutritional DiagnosticsInnovations like smartphone-compatible devices (e.g., Cornell's NutriPhone) can measure iron, vitamin A, D, and B12 from just a finger-prick in minutes—indicating a shift toward compact, multipurpose diagnostics useful in both clinics and homes. Artificial Intelligence–Enhanced Digital Nucleic Acid Amplification (dNAAT)Cutting-edge techniques such as digital PCR (dPCR) and digital LAMP (dLAMP), combined with AI-powered image analysis, are enhancing diagnostic precision and sensitivity. These advancements pave the way for scalable, faster, and more accurate molecular testing, even at the point of care. In Vitro Diagnostics Market Opportunity What is the Opportunity for the In Vitro Diagnostics Market? The growing prevalence of chronic diseases like cancer, diabetes, and cardiovascular diseases increases demand for in vitro diagnostics for early detection of diseases. The increasing patient demand for early detection of chronic diseases increases demand for IVD tests. The increasing demand for tracking the progression of chronic diseases increases the adoption of IVD for managing disease effectively and adjusting treatment plans. The increasing development of personalised treatment requires IVD technologies. The availability of point-of-care testing increases adoption of IVD for efficient management of chronic conditions. The increasing awareness of early disease detection and the increasing demand for regular health check-ups increase the adoption of IVD. The growing prevalence of chronic diseases creates an opportunity for the growth of the in vitro diagnostics market. In Vitro Diagnostics Market Challenges and Limitations and Challenges: Why High Development Cost Limitation for the In Vitro Diagnostics Market? Despite several benefits of in vitro diagnostics in various disease diagnoses, the high development cost restricts the market growth. Factors like the need for extensive clinical validation, the complex nature of IVD platforms, stricter regulation, high investment in R&D, and intensive clinical trials are responsible for high development costs. The need for high investment in personnel, equipment, and reagents directly affects the market. The complexity of IVD technologies and lengthy development cycles increases the production costs. The stricter regulations for the development of IVD tests require a high cost. The need for extensive compliance, documentation, and quality assurance requires a high cost. The requirement of specialized materials and precision manufacturing increases the production cost. The high development cost hampers the growth of the in vitro diagnostics market. Scope of the In Vitro Diagnostics Market Report Attributes Key Statistics Market Size in 2025 USD 104.10 Billion Market Size in 2030 USD 117.18 Billion Market Size in 2032 USD 124.66 Billion Market Size by 2034 USD 132.07 Billion Growth Rate 2025-2034 CAGR of 2.30% Base Year 2024 Forecast Period 2025 to 2034 Historical Data 2021 to 2023 Largest Regional Market (2024) North America – 42% revenue share Fastest Growing Regional Market Asia Pacific Segments Covered Product, Technology, Application and Regions Regions Covered North America, APAC, Europe, Latin America, MEAN, Rest of the World Key Players Covered Alere, Inc., Hoffmann-La Roche Ltd., Arkray,Beckman Coulter, Becton Disckinson, Bio-Rad laboratories, Danaher, Sysmex Corporation, Abbott Laboratories and other ➡️ Become a valued research partner with us ☎ How Big is the U.S. In Vitro Diagnostics (IVD) Market? According to Precedence Research, the U.S. in vitro diagnostics (IVD) market size was evaluated at USD 34.98 billion in 2024 and is expected to rise from USD 35.43 billion in 2025 to approximately USD 42.55 billion by 2034, at a CAGR of 2.20% from 2025 to 2034. The Complete Study is Immediately Accessible | Download the Sample Pages of this Report@ U.S. In Vitro Diagnostics Market Key Takeaways The U.S. in vitro diagnostics market reached USD 34.98 billion in 2024. It is projected to hit around USD 42.63 billion by 2034. The market is growing at a CAGR of 2% from 2025 to 2034. By product, the reagents segment held the highest share of 67% in 2024. By test location, the point-of-care segment dominated the market in 2024. By technology, the Immunoassay segment is expected to grow at a significant CAGR from 2025 to 2034. By application, the infectious diseases segment dominated the market with the biggest market share in 2024. By application, the oncology segment is expected to witness the fastest CAGR of growth during the forecast period of 2025-2034. By end user, the hospital segment held the dominating share of the market in 2024. U.S. In Vitro Diagnostics Market Leading Companies Alere, Inc. Beckman Coulter BD Bio-Rad laboratories Danaher Abbott Laboratories Thermo Fisher Scientific Inc. bioMérieux, Inc Quest Diagnostics Illumina, Inc. Get Immediate Access – Secure Your Copy of This Premium Research Report@ Which Region Dominated the In Vitro Diagnostics Market? North America dominated the in vitro diagnostics market in 2024. The well-established healthcare infrastructure, like research centers, modern clinical laboratories, and hospitals, increases the adoption of IVD. The ongoing technological innovations like digital health integration, high-throughput systems, and lab-on-a-chip equipment in IVD help the market growth. The increasing prevalence of infectious and chronic diseases increases the adoption of IVD. The increasing healthcare spending and focus on personalised medicine increase the adoption of IVD. The presence of major players like BD, Abbott, and Thermo Fisher Scientific drives the market growth. Why Asia Pacific Experiencing the Fastest Growth in the In Vitro Diagnostics Market? Asia Pacific is experiencing the fastest growth in the market during the forecast period. The growing prevalence of chronic diseases like cancer, diabetes, and cardiovascular diseases increases the adoption of IVD. The growing government investment in healthcare infrastructure and increasing spending on diagnostics increases demand for IVD, helping the market growth. The increasing awareness about the early detection of diseases and the growing expansion of healthcare facilities like clinics & hospitals increases adoption of IVD, supporting the overall growth of the market. 'The integration of AI with molecular diagnostics will reshape IVD workflows over the next decade, improving test turnaround times and accuracy, particularly in decentralized settings,' said Deepa Pandey, Principal Consultant at Precedence Research. In Vitro Diagnostics Market Segmentation Analysis: Product Analysis: Why did Reagent Segment Dominate the In Vitro Diagnostics Market? The reagent segment dominated the in vitro diagnostics market in 2024. The compatibility of reagents with various diagnostics platforms, like point-of-care, clinical laboratories, and hospitals, helps the market growth. The growth in personalised medicine increases the adoption of reagents. The growth in diagnostics like oncology, infectious diseases, and chronic diseases increases the adoption of reagents. The growing utilization of molecular diagnostic techniques increases demand for reagents, driving the overall growth of the market. The instruments segment is the fastest-growing in the market during the forecast period. The growing prevalence of chronic diseases like cardiovascular conditions, diabetes, and cancer increases demand for instruments for early detection. The increasing focus on early detection of diseases and timely treatment increases demand for instruments. The ongoing innovations in diagnostic technologies and the expansion of point-of-care testing support the market growth. Technology Analysis: How Immunoassay Segment Held the Largest Share in the In Vitro Diagnostics Market? The immunoassay segment held the largest revenue share in the in vitro diagnostics market in 2024. The increasing detection of various analytes like proteins, drugs, hormones, and antibodies increases the adoption of immunoassays. The increasing demand for ELISA and CLIA immunoassays helps the market growth. The increasing demand for POC testing and the increasing availability of central labs increase the adoption of immunoassays. The increasing risks of infectious diseases and chronic diseases increase demand for immunoassay-based diagnosis, driving the overall market growth. The molecular diagnostics segment is experiencing the fastest growth in the market during the forecast period. The growing utilization of techniques like next-generation sequencing & PCR for early disease diagnosis helps the market growth. The increased spread of infectious diseases increases the adoption of molecular diagnostics to control the spread of disease. The increasing development of personalised medicine and growth in at-home testing & point-of-care fuels demand for molecular diagnostics, supporting the overall market growth. Application Analysis: Which Application Segment Dominated the In Vitro Diagnostics Market? The oncology segment dominated the in vitro diagnostics market in 2024. The increasing prevalence of cancer increases demand for IVD for accurate diagnosis and early detection of conditions. The ongoing advancements in molecular diagnostics, like liquid biopsies and next-generation sequencing, help in the market growth. The increasing demand for early detection of cancer and the growth in the development of personalised medicines increases the demand for IVD. The increasing demand for IVD tests for various cancers like lung, prostate cancers, breast cancers, and colorectal drives the market growth. The infectious disease segment is the fastest-growing in the market during the forecast period. The growth in infectious diseases like viral outbreaks, respiratory infections, and STDs increases demand for IVD. The increasing awareness about the early detection of infectious diseases and focus on reducing transmission increases the adoption of IVD. The increasing prevalence of hepatitis, HIV, and tuberculosis increases demand for IVD, supporting the overall market growth. Test Location Analysis: How Point of Care Segment Held the Largest Share in the In Vitro Diagnostics Market? The point of care segment held the largest revenue share in the in vitro diagnostics market in 2024. The increasing demand for faster test results and focus on reducing turnaround times increases the adoption of point of care. The increasing need for IVD tests in underserved and remote areas increases the adoption of IVD. The focus on the management of chronic conditions like cardiovascular diseases and diabetes increases demand for POC. The increasing suitability of POC in various settings like doctors' offices, hospitals, and clinics drives the market growth. The home care segment is experiencing the fastest growth in the market during the forecast period. The growing patients' preference for testing at home and the growing expansion of home-based testing help the market growth. The increasing development of automated, user-friendly, and portable IVD devices increases adoption of care. The increasing management of chronic conditions like cardiovascular diseases & diabetes increases demand for home care, supporting the overall growth of the market. End User Analysis: Why did the Hospital Segment Dominate the In Vitro Diagnostics Market? The hospitals segment dominated the in vitro diagnostics market in 2024. The high availability of a wide range of diagnostic tests and the increasing number of patients increase the adoption of hospitals. The growing demand for accurate and early diagnosis of diseases increases the demand for hospitals. The availability of advanced technologies like molecular diagnostic tools, automated analyzers, and others helps the market growth. The presence of trained personnel, well-established infrastructure, and high-quality equipment in hospitals drives the market growth. Related Topics You May Find Useful: ➢ In-Vitro Inflammatory Bowel Disease Diagnostics Market: Uncover how biomarker innovations are transforming early IBD detection ➢ Infectious Disease In-Vitro Diagnostics Market: Explore rising demand for rapid pathogen testing and accuracy-driven diagnostics ➢ In-Vitro Diagnostics Enzymes Market: See how enzyme-based assays are becoming indispensable in chronic disease detection ➢ Diagnostic Testing Market: Track how expanding cardiology testing and hospital-led diagnostics are reshaping global healthcare ➢ Next-Generation IVD Market: Dive into how AI, genomics, and precision medicine are redefining diagnostic frontiers ➢ Cancer IVD Market: Analyze how early cancer detection and immunoassays are fueling a surge in diagnostic innovation ➢ Cancer Diagnostics Market: Discover how hospital-led screening and consumables-led solutions are doubling market size by 2034 ➢ DNA Diagnostics Market: Explore how PCR tech and oncology testing are powering DNA testing's rapid growth ➢ IVD Contract Manufacturing Market: Understand how outsourcing efficiencies and consumable demand are driving diagnostic scale-up ➢ In-Vitro Colorectal Cancer Screening Tests Market: Track rising demand for non-invasive CRC screening and lab-based diagnostics In Vitro Diagnostics Market Top Companies Alere, Inc. Hoffmann-La Roche Ltd. Arkray Beckman Coulter Becton Dickinson Bio-Rad Laboratories Danaher Sysmex Corporation Abbott Laboratories Recent Developments: In August 2024, InBios launched an in vitro diagnostic test, a serological ELISA kit for strongyloidiasis. The kit provides results under 75 minutes and is intended for use only in patients with symptoms, clinical history, and signs. (Source: In June 2023, GenWorks Health launched IVD tests for malaria & dengue. The test kits include iScreen Dengue NS1 and iScreen Malaria Card Antigen. The IVD products aim to diagnose, treat, prevent, and cure seasonal diseases. (Source: In September 2023, NeoDx Biotech launched an IVD kit, the HLA-B27 RT-PCR kit for detecting autoimmune disorders. The kits help to analyze disorders like psoriasis, reactive arthritis, ankylosing spondylitis, and inflammatory bowel syndrome. (Source: Case Study: AI-Powered Molecular Diagnostics at Sunrise Labs Boosts Cancer Detection Rates Sunrise Labs, a leading diagnostic center network in Southeast Asia, faced challenges in delivering early, accurate cancer diagnoses to patients in semi-urban and rural areas. Traditional lab workflows required samples to be shipped to centralized facilities, causing delays of 3–5 days before results reached clinicians. Solution Implemented: In 2023, Sunrise Labs partnered with a global IVD leader to deploy a portable, AI-enhanced molecular diagnostics platform capable of running PCR-based oncology tests on-site. The system integrated with the lab's electronic health record (EHR) system, enabling seamless data transfer and analysis. Key Innovations: Point-of-Care Molecular Testing: Allowed oncologists to receive results within 90 minutes. AI-Driven Image Analysis: Improved detection accuracy for early-stage cancers by 18% compared to conventional lab workflows. Custom Reagent Kits: Designed for tropical climates to maintain stability without cold-chain dependency. Results Achieved: Turnaround Time Reduced: From 3–5 days to under 2 hours. Screening Uptake Increased: 35% more patients underwent cancer screening in the first year. Cost Efficiency: Operational costs dropped by 22% due to reduced logistics and sample handling. Patient Outcomes: Early detection rates for breast and cervical cancer improved, enabling earlier treatment interventions. Industry Implication: This case underscores how integrating AI with IVD molecular diagnostics can dramatically improve accessibility and patient outcomes in emerging markets, aligning with broader industry trends toward decentralization and personalized medicine. It also highlights the commercial potential for IVD players to target underserved regions with tailored product designs. In Vitro Diagnostics Market Segments Covered in the Report By Product Reagents Instruments Services By Test Location Point of Care Home Care Others By Technology Immunoassay Instruments Reagents Services Hematology Instruments Reagents Services Clinical Chemistry Instruments Reagents Services Molecular Diagnostics Instruments Reagents Services Coagulation Instruments Reagents Services Microbiology Instruments Reagents Services Others Instruments Reagents Services By Application Diabetes Cardiology Nephrology Infectious Disease Oncology Drug Testing Autoimmune Diseases Others By End User Hospitals Standalone Laboratories Academic & Medical Schools Point-of-Care Others By Region North America U.S. Canada Europe Germany UK France Italy Spain Sweden Denmark Norway Asia Pacific China Japan India South Korea Thailand Latin America Brazil Mexico Argentina Middle East & Africa South Africa UAE Saudi Arabia Kuwait Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as Immediate Delivery Available | Buy This Premium Research Report@ You can place an order or ask any questions, please feel free to contact at sales@ | +1 804 441 9344 Stay Ahead with Precedence Research Subscriptions Unlock exclusive access to powerful market intelligence, real-time data, and forward-looking insights, tailored to your business. From trend tracking to competitive analysis, our subscription plans keep you informed, agile, and ahead of the curve. Browse Our Subscription Plans@ About Us Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. Web: Our Trusted Data Partners: Towards Healthcare | Towards Packaging | Towards Automotive | Towards Chem and Materials | Towards FnB | Towards Consumer Goods | Statifacts | Towards EV Solutions | Towards Dental | Nova One Advisor | Market Stats Insight Get Recent News: For the Latest Update Follow Us: LinkedIn | Medium | Facebook | Twitter ✚ Explore More Market Intelligence from Precedence Research: ➡️ In-Vitro Fertilization Market: Explore how technological advances and rising infertility treatments are driving global IVF demand ➡️ Artificial Intelligence Diagnostics Market: See how AI-powered tools are revolutionizing accuracy and speed in clinical diagnostics ➡️ Non-Invasive Cancer Diagnostics Market: Discover how liquid biopsies and imaging innovations are reshaping cancer detection ➡️ Home Diagnostics Market: Track how convenience and digital health integration are fueling at-home testing adoption ➡️ Point-of-Care Diagnostics Market: Understand how rapid testing solutions are transforming care delivery in clinics and beyond ➡️ Infectious Respiratory Disease Diagnostics Market: Analyze demand shifts driven by pandemic preparedness and respiratory health awareness ➡️ Breast Cancer Diagnostics Market: Learn how imaging, biopsy, and AI tools are advancing early breast cancer detection ➡️ Point-of-Care Molecular Diagnostics Market: Explore how portable PCR and molecular tools are enhancing real-time diagnosis ➡️ Rapid Diagnostics Market: See how speed, accuracy, and accessibility are redefining modern diagnostics ➡️ Next-Generation Cancer Diagnostics Market: Discover how genomic profiling and precision oncology are shaping next-gen cancer testing ➡️ Tissue Diagnostics Market: Understand how histopathology innovations are improving disease characterization ➡️ Blood Transfusion Diagnostics Market: Track advances in screening technologies ensuring safer transfusion practices ➡️ Infectious Disease Diagnostics Market: Explore how rising disease outbreaks are accelerating global diagnostic capabilities ➡️ Point-of-Care Infectious Disease Diagnostics Market: See how rapid and mobile solutions are revolutionizing infectious disease management ➡️ DNA Diagnostics Market: Learn how genetic testing is unlocking new frontiers in personalized medicine ➡️ Infectious Disease In-Vitro Diagnostics Market: Discover how innovation in IVD is boosting accuracy in pathogen detectionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Healthcare Activation Company, Pyx Health, Ranks No. 661 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
Healthcare Activation Company, Pyx Health, Ranks No. 661 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies

Yahoo

time26 minutes ago

  • Yahoo

Healthcare Activation Company, Pyx Health, Ranks No. 661 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies

With Three-Year Revenue Growth of 631% Percent, This Marks Pyx Health's Fourth Consecutive Appearance on the List NEW YORK, August 12, 2025--(BUSINESS WIRE)--In its annual list of the fastest growing private companies in America, leading media brand Inc. today revealed that Pyx Health has ranked number 661, denoting its fourth consecutive appearance on the Inc. 5000. The prestigious list is a data driven snapshot of the companies experiencing the most success in today's economy, with giants like Microsoft, Meta, Chobani, Under Armour, Timberland, and more previously earning a coveted spot. Founded in 2017, Pyx Health is a member activation company that improves quality outcomes for health plans and their members. Pyx blends personalized technology, real human connection and home-delivered resources to engage members, motivate them, and support taking action to improve their health. Through their offering, Pyx identifies hidden risks, addresses non-medical drivers of health (NMDoH) like transportation to appointments or food insecurity, and helps close gaps in care, ultimately delivering better outcomes for members and reducing healthcare spending. Achieving considerable success since its origins, since late 2023, Pyx Health acquired chronic disease management platform InquisitHealth to supercharge its tech-enablement, and co-founders Cindy and Anne Jordan most recently raised $47.5 million in the lead-up to Pyx's acquisition of food-as-engagement company FarmboxRx. These acquisitions marked a significant milestone for the brand as it continues to expand beyond its roots as a loneliness point solution to fully encircle members with support for the breadth of non-medical barriers to care, like food insecurity – a pervasive and significant need among the CMS populations Pyx Health serves. "Being named in the Inc. 5000 for the fourth consecutive year is a powerful validation of not just our growth, but of our mission to address NMDoH and expand access to care for underserved populations," said Cindy Jordan, CEO and Co-Founder of Pyx Health. "At a time when policy changes threaten to strip vital benefits and access to care from society's most vulnerable populations, our work is more urgent than ever. We're committed to continuing to meet people where they are, with compassion, technology, and a belief that no one should have to navigate their health alone." Pyx's appearance on the list denotes exceptional growth while navigating economic uncertainty, inflationary pressure, and an ever-changing landscape in the healthcare industry. Among the top 500 companies on the list, the median three-year revenue growth rate reached 1,552 percent, and those companies have collectively added more than 48,678 jobs to the U.S. economy over the past three years. "Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision," says Mike Hofman, editor-in-chief of Inc. "These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy." Inc. will celebrate the honorees at the 2025 Inc. 5000 Conference & Gala, taking place October 22–24 in Phoenix, and the top 500 will be listed in the Fall issue of Inc. magazine. For the full list, company profiles, and a searchable database by industry and location, visit: To learn more about Pyx Health, please visit: Methodology Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit About Pyx Health: Pyx Health is a healthcare activation company on a mission to help health plans engage the members who are hardest to reach, through personalized technology, real human connection and home-delivered resources. Pyx Health's platform is able to identify hidden risks, close gaps in care and address non-medical drivers of health, ultimately helping to overcome barriers to care, and deliver better outcomes for members and stronger impact for health plans. For more information, visit us at and follow us on LinkedIn and Facebook. Because no one gets better alone™. View source version on Contacts Media Contact:Mia HinzSolCommspyxhealth@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Research-Grade Proteins Market to Expand at 15.57% CAGR by 2034
Research-Grade Proteins Market to Expand at 15.57% CAGR by 2034

Yahoo

time26 minutes ago

  • Yahoo

Research-Grade Proteins Market to Expand at 15.57% CAGR by 2034

The global research-grade proteins market will grow from USD 1.31 billion in 2025 to around USD 4.81 billion by 2034, expanding at a CAGR of 15.57% during the forecast period. Ottawa, Aug. 12, 2025 (GLOBE NEWSWIRE) -- According to a study published by Towards Healthcare, a sister firm of Precedence Research, the global research-grade proteins market size will grow from USD 1.13 billion in 2024 to around USD 4.81 billion by 2034, expanding at a CAGR of 15.57%. The growth of the market is driven by advancements in proteomics research, increased R and D investments, and personalized medicine, which has increased the growth of the market. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the research-grade proteins market share by 45%. Asia Pacific is estimated to host the fastest-growing research-grade proteins market during the forecast period. By product, the cytokines & growth factors segment held the largest share of the research grade proteins market in 2024 and is estimated to grow at the fastest CAGR during the forecast period. By host cell, the mammalian cells segment held the largest research-grade proteins market share in 2024. By host cell, the bacterial cells segment is anticipated to achieve the fastest growth rate in the research-grade proteins market during the predicted timeframe. By end-use, the pharmaceutical & biotechnology companies segment dominated the research grade proteins market in 2024. Market Overview & Potential Proteins that have been manufactured and refined to exacting standards of quality and purity, especially for use in scientific research, are known as research-grade proteins. Molecular biology, biochemistry, cell biology, and drug discovery are just a few of the many experimental and analytical fields in which these proteins are essential. For examining the structure, connections, and function of proteins as well as for creating new treatment approaches, they are essential resources. Proteomics and genomics advancements, growing applications in drug development, the adoption of advanced research tools in the biotechnology and pharmaceutical sectors, and increased awareness of innovative technologies are some of the major trends anticipated during the forecast period. What is the Growth Potential Responsible for the Growth of the research-grade proteins market? The growth of the market is driven by the growing demand for specific protein types like recombinant proteins, antibodies, and enzymes for therapies and treatment of autoimmune diseases, immune checkpoint proteins and cytokines, and growth factors for inflammation and regenerative medicine, which influences the growth of the market. The technological advancements, like protein engineering and expression, along with advancements in purification and analysis, influence the growth of the market. The expanding applications like clinical trials, the biopharmaceutical industry, and academic and research institutions, fuel the growth of the market, supporting the expansion of the market. You can place an order or ask any questions, please feel free to contact us at sales@ What Are the Growing Trends Associated With the Research-Grade Proteins Market? Increased R&D Funding Government and academic institutions increased research and development funding for innovation increases the growth of the market. Biopharmaceutical Industry Growth The growing need for high-quality protein in drug discovery and development influences the growth of the industry, driving demand in the market. Personalized Medicine The demand for personalized medicines due to the growing geriatric population which increases the demand for specific protein research tools. Proteomics Advancements Progress in proteomics for structure and function advancements fuels the growth of the market. Demand for Advanced Research Tools The need for reliance and precision in the research tools in biotechnology and pharmaceutical research is increasing, fueling the growth. What Is the Growing Challenge In the Research-Grade Proteins Market? The key challenge which hinders the growth of the market are the stringent standards, regulatory mandates, contamination control, data integrity, variability and reproducibility are some of the challenges which limits the growth of the market. The other major challenge is the high production cost, which includes licensing fees, stable expression system, capital, and operational expenses, limiting the scalability, which hinders the growth and expansion of the market. Become a valued research partner with us - Regional Analysis How Did North America Dominate The Research-Grade Proteins Market In 2024? North America dominated the research-grade proteins market in 2024. The U.S. and Canada play important roles. With significant investments in research and development, the U.S., home to a thriving biotechnology and pharmaceutical sector, drives market growth. The rising demand for premium proteins is mainly fueled by large research institutes, biotech firms, and pharmaceutical conglomerates. Canada also makes a notable contribution, thanks to its growing bio-sciences industry and strong university research base. Supporting the region's dominance are advanced technical infrastructure, a robust regulatory environment, and a proactive approach to adopting cutting-edge research-grade protein solutions, all of which help establish North America as a key hub in this expanding industry. What Made Asia Pacific Significantly Grow In The Research-Grade Proteins Market In 2024? Asia Pacific is estimated to host the fastest-growing research-grade proteins market during the forecast period. Increasing knowledge of advanced technology, expansion of healthcare infrastructure, and a higher demand for innovative diagnostics and potent treatment options are all driving this rapid growth. Additionally, the region's emerging economies are making investments in research facilities and biotechnology infrastructure. The potential of the region is further strengthened by the rising number of clinical trials focused on cancer research and drug development, positioning it as a key area for expansion in the coming years. Get the latest insights on healthcare industry segmentation with our Annual Membership: Segmental Insights By product, Which Product Type Segment Dominated The Research Grade Proteins Market In 2024? The cytokines & growth factors segment held the largest share of the research grade proteins market in 2024 and is estimated to grow at the fastest CAGR during the forecast period. Cytokines and growth factors are widely used research-grade proteins that play a crucial role in cell signaling, immune response, and tissue regeneration studies. They are vital in stem cell research, cancer biology, and immunology for understanding disease mechanisms and therapeutic development. The increasing focus on regenerative medicine and cell-based assays is driving demand for high-purity, recombinant cytokines and growth factors across academic, pharmaceutical, and biotechnology research settings. By the host cell, How Did Mammalian Cell Segment Dominated The Research Grade Proteins Market In 2024? The mammalian cells segment held the largest research-grade proteins market share in 2024. Mammalian cells are a preferred host for producing research-grade proteins due to their ability to perform complex post-translational modifications, ensuring structural and functional similarity to native human proteins. These cell lines, such as CHO and HEK293, are extensively used in producing cytokines, enzymes, and antibodies. Their widespread use in biomedical and pharmaceutical research boosts demand, especially for applications requiring high bioactivity and accurate protein folding. The bacterial cells segment is anticipated to achieve the fastest growth rate in the research-grade proteins market during the predicted timeframe. Bacterial cells, particularly Escherichia coli, are widely used as host systems for producing research-grade proteins due to their rapid growth, low production cost, and scalability. They are ideal for synthesizing non-glycosylated proteins such as enzymes and structural proteins. Despite limitations in post-translational modifications, bacterial expression systems remain popular in academic and industrial research for producing large quantities of recombinant proteins efficiently and cost-effectively. By end-use, Which End-Use Segment Dominated The Research Grade Proteins Market In 2024? The pharmaceutical & biotechnology companies segment dominated the research grade proteins market in 2024. Pharmaceutical and biotechnology companies are major end users of research-grade proteins for drug discovery, target validation, and preclinical development. These proteins are essential for high-throughput screening, functional assays, and the development of biologics. The growing pipeline of protein-based therapeutics and the demand for precision research tools are driving consistent demand from this segment, supported by increasing R&D investments and advancements in protein engineering technologies. Recent Developments In July 2024, with its widely used qPCR equipment, Spear Bio Inc., a biotechnology business that makes it possible to detect protein molecules down to dozens of copies, reported that its $45 million Series A fundraising was successfully closed. In June 2024, the novel protein synthesis platform was introduced by Syngene International Ltd. With the use of Syngene's clone selection and development procedures and a cell line and transposon-based technology licensed from Swiss biotech services provider ExcellGene, the platform seeks to significantly increase accuracy and efficiency. Research Grade Proteins Market Key Players Thermo Fisher Scientific, Inc. Abcam Plc Miltenyi Biotec GenScript Bio-Techne Proteintech Group, Inc. ACROBiosystems Sino Biological, Inc. Prospec-Tany Technogene Ltd. New England Biolabs Browse More Insights of Towards Healthcare: The global host cell protein testing market reached USD 2.37 billion in 2024, grew to USD 2.56 billion in 2025, and will likely reach USD 5.19 billion by 2034, expanding at a CAGR of 8.17% from 2025 to 2034. The global protein expression technology market recorded USD 2.85 billion in 2024, rose to USD 3.05 billion in 2025, and is on track to hit USD 5.58 billion by 2034, growing at a CAGR of 6.94% from 2025 to 2034. The global proteinase K market stood at USD 4.82 billion in 2024, increased to USD 5.23 billion in 2025, and will likely reach USD 10.93 billion by 2034, advancing at a CAGR of 8.54% from 2025 to 2034. The global cell-free protein expression market totaled USD 315.03 million in 2024, rose to USD 342.25 million in 2025, and is projected to climb to USD 716.26 million by 2034, expanding at a CAGR of 8.63% from 2025 to 2034. The global protein therapeutics market was valued at USD 375.3 billion in 2024, increased to USD 401.89 billion in 2025, and will likely surge to USD 740.07 billion by 2034, growing at a CAGR of 7.08% from 2025 to 2034. The global protein engineering market reached USD 3.08 billion in 2024, grew to USD 3.58 billion in 2025, and is poised to hit USD 13.84 billion by 2034, expanding at a robust CAGR of 16.27% from 2025 to 2034. The global PEGylated proteins market stood at USD 1.63 billion in 2024, rose to USD 1.82 billion in 2025, and is expected to reach USD 4.95 billion by 2034, advancing at a CAGR of 11.74% from 2025 to 2034. The global G-protein coupled receptors market recorded USD 3.86 billion in 2024, grew to USD 4.06 billion in 2025, and is on course to reach USD 6.37 billion by 2034, increasing at a CAGR of 5.14% from 2024 to 2034. The global C-reactive protein testing market registered USD 5.58 billion in 2024, slightly rose to USD 5.6 billion in 2025, and is expected to reach USD 5.75 billion by 2034, expanding marginally at a CAGR of 0.3% from 2024 to 2034. The global plasma protein products market was worth USD 32.8 billion in 2023 and is projected to grow to USD 72.9 billion by 2034, rising at a CAGR of 7.53% from 2024 to 2034. Segments Covered in The Report By Product Cytokines & Growth Factors Interferons (IFNs) Interleukins (ILs) Others Antibodies Immune Checkpoint Proteins Virus Antigens Enzymes Kinases Metabolic Enzymes Others Recombinant Regulatory Proteins Hormones Others By Host Cell Mammalian Cells Bacterial Cells Fungi & Yeast Insect Cells Others By End-use Pharmaceutical & Biotechnology Companies Academic & Research Institute Others By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Immediate Delivery Available | Buy This Premium Research @ Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway Access the Dashboard: About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | Instagram

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store